

Supplemental Table 1. RA status and baseline variables

	Anti-CCP- /DMARD* use		Anti-CCP+/no DMARD use		Anti- CCP+/DMARD use		Anti-CCP-/no DMARD use		No RA	
	N	%	N	%	N	%	N	%	N	%
	Age									
50-59	56	25.8	166	30.9	79	28.7	2687	30.0	44708	33.4
60-69	103	47.5	249	46.4	132	48.0	4004	44.7	60222	45.0
70-79	58	26.7	122	22.7	64	23.3	2267	25.3	28811	21.5
Ethnicity										
Black	41	18.9	188	35.0	47	17.1	2166	24.2	11466	8.6
Hispanic	5	2.3	48	8.9	18	6.6	987	11.0	4983	3.7
White	171	78.8	301	56.1	210	76.4	5805	64.8	117292	87.7
Education										
≤ High school	57	26.4	162	30.6	57	21.0	2885	32.5	28485	21.5
Some college	83	38.4	213	40.3	121	44.7	3477	39.2	20113	37.8
≥ College	76	35.2	154	29.1	93	34.3	2503	28.2	54161	40.8
Smoking										
Never	96	44.7	206	39.2	113	41.7	4505	51.1	66630	50.4
Past	104	48.4	245	46.6	138	50.9	3557	40.4	56458	42.7
Current	15	7.0	75	14.3	20	7.4	751	8.5	9095	6.9
General health										
Excellent/very good	50	23.2	177	33.4	59	21.8	3338	37.6	80457	60.5
Good	108	50.0	223	42.1	125	46.1	3640	41.1	42353	31.8
Fair/poor	58	26.9	130	24.5	87	32.1	1890	21.3	10243	7.7
Hypertension										
No	123	57.5	316	59.2	183	67.0	4843	54.7	89578	67.3
Yes	91	42.5	218	40.8	90	33.0	4005	45.3	43463	32.7

Supplemental Table 1 cont'd

Diabetes										
No	191	88.0	496	92.4	259	94.2	7990	89.3	126399	94.6
Yes	26	12.0	41	7.6	16	5.8	962	10.8	7266	5.4
CHD at baseline										
No	192	88.5	491	91.4	248	90.2	7684	85.8	125372	93.7
Yes	25	11.5	46	8.6	27	9.8	1274	14.2	8369	6.3
Stroke at baseline										
No	214	98.6	526	98.0	270	98.2	8735	97.5	132060	98.8
Yes	3	1.4	11	2.1	5	1.8	222	2.5	1646	1.2
BMI >30										
30-34.9	39	18.1	121	22.7	43	15.7	2069	23.3	24276	18.32
35-39.9	25	11.6	33	6.2	26	9.5	1052	11.9	9668	7.3
40+	12	5.6	27	5.1	6	2.2	678	7.6	5014	3.8
Total METs per week										
<2.5	77	35.7	185	35.6	92	33.8	2685	31.0	32359	24.9
2.5-18.4	110	50.9	240	46.2	138	50.7	4241	49.0	65314	50.3
≥18.25	29	13.4	95	18.3	42	15.4	1728	20.0	32272	24.8

Supplemental Table 2. Characteristics of study sample (N=9,988) according to timing of RA report (baseline or follow-up)

	Total	DMARD use at					
		Anti-CCP+		baseline		Deaths	
		N	%	N	%	N	%
RA at both baseline and follow up							
Black	383	70	18.3	33	8.6	46	12.0
Hispanic	158	21	13.3	11	7.0	9	5.7
White	1109	149	13.4	105	9.5	178	16.1
		p=0.061		p=0.560		p=0.001	
RA at baseline only							
Black	777	79	10.2	44	5.7	111	14.3
Hispanic	209	20	9.6	10	4.8	19	9.1
White	3018	273	9.05	258	8.5	505	16.7
		p=0.619		p=0.007		p=0.005	
RA at follow up only							
Black	1282	86	6.7	11	0.9	114	8.9
Hispanic	691	25	3.6	2	0.3	39	5.6
White	2354	89	3.8	18	0.8	304	12.9
		p=0.0001		p=0.332		p=<0.001	
Total	9981	812	8.1	492	4.9	1325	13.3

Supplemental Table 3. Cause of death by anti-CCP+ or ⁻ and DMARD use for women who self-reported RA at baseline or baseline and follow up

	Anti-CCP+	Anti-CCP-/DMARD use	Anti-CCP-/No DMARD
	N (%)	N (%)	Use
	Total deaths= 120	Total deaths= 29	N (%)
			Total deaths = 632
Dementia	2 (1.7)	2 (6.9)	10 (1.6)
Respiratory	11 (9.2)	2 (6.9)	42 (6.6)
Pneumonia	4 (3.3)	1 (3.4)	23 (3.6)
Infection	2 (1.7)	0. (0.0)	3 (0.5)
Sepsis	4 (3.3)	2 (6.9)	12 (11.9)
Renal failure	1 (0.8)	--	8 (1.3)
Coronary heart disease	23(19.2)	9 (31.0)	143 (22.6)
Cerebrovascular disease	8 (6.7)	1 (3.4)	48 (7.6)
Congestive heart failure	7 (5.8)	1 (3.4)	12 (1.9)
Other atherosclerosis (not CHD or CVD)	3 (2.5)	0 (0.0)	13 (2.1)
Other heart not CHD	1 (0.8)	0 (0.0)	18 (2.8)
Breast cancer	4 (3.3)	0 (0.0)	26 (4.1)
Ovarian cancer	3 (2.5)	0 (0.0)	13 (2.1)
Colon cancer	2 (1.7)	--	23 (3.6)
Other cancers	23 (19.2)	3 (10.3)	125 (19.8)
Accident	3 (2.5)	1 (3.4)	19 (3.0)
All other	19 (15.8)	7 (24.1)	94 (14.9)

Supplemental Table 4. Creatinine levels and RA baseline and percent dead by anti-CCP+/-

	Creatinine Levels mg/dl								Total
	0.10-0.40		0.50-0.59		0.60-0.79		>0.80		
	N	% Dead	N	% Dead	N	% Dead	N	% Dead	
Anti-CCP+	121	16	112	21	148	12	61	31	442
Anti-CCP-/no	24	21	48	23	82	12	36	31	190
DMARD use									

For Peer Review


Supplemental Figure Legends

Supplemental Figure 1. Sampling Frame For the Women's Health Initiative Study


Supplemental Figure 2. Mortality at 2009 by Age and Ethnicity Groups, Excluding RA at Follow Up Only

Supplemental Figure 3. Age-adjusted Death Rate by Anti-CCP+, DMARD Use and Joint Pain, Among Women Who Have Not Reported RA


For Peer Review




Review




Review



Review




Supplemental Figure 1. Sampling Frame For the Women's Health Initiative Study
254x190mm (96 x 96 DPI)



Supplemental Figure 2. Mortality at 2009 by Age and Ethnicity Groups, Excluding RA at Follow Up Only
254x190mm (96 x 96 DPI)

Review



Supplemental Figure 3. Age-adjusted Death Rate by Anti-CCP+, DMARD Use and Joint Pain, Among Women Who Have Not Reported RA
254x190mm (96 x 96 DPI)

Review